Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 1
1966 2
1967 1
1968 2
1970 1
1971 1
1973 1
1974 1
1975 1
1976 2
1978 2
1979 2
1980 4
1981 2
1982 4
1983 2
1984 8
1985 6
1986 12
1987 7
1988 7
1989 27
1990 11
1991 7
1992 10
1993 13
1994 10
1995 8
1996 10
1997 3
1998 3
1999 12
2000 10
2001 6
2002 12
2003 11
2004 11
2005 9
2006 14
2007 24
2008 14
2009 29
2010 22
2011 26
2012 27
2013 19
2014 9
2015 19
2016 12
2017 11
2018 19
2019 13
2020 16
2021 13
2022 10
2023 7
Text availability
Article attribute
Article type
Publication date

Search Results

492 results
Results by year
Filters applied: . Clear all
Page 1
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: tsukamoto n. Hematol Oncol. 2022 Oct;40(4):667-677. doi: 10.1002/hon.2977. Epub 2022 Mar 2. Hematol Oncol. 2022. PMID: 35142384
Immune-resistant mechanisms in cancer immunotherapy.
Kawakami Y, Ohta S, Sayem MA, Tsukamoto N, Yaguchi T. Kawakami Y, et al. Among authors: tsukamoto n. Int J Clin Oncol. 2020 May;25(5):810-817. doi: 10.1007/s10147-019-01611-x. Epub 2020 Jan 9. Int J Clin Oncol. 2020. PMID: 31919690 Review.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: tsukamoto n. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. Haematologica. 2023. PMID: 36200417 Free PMC article.
Primary cervical choriocarcinoma.
Tsukamoto N, Nakamura M, Kashimura M, Saito T. Tsukamoto N, et al. Gynecol Oncol. 1980 Feb;9(1):99-107. doi: 10.1016/0090-8258(80)90014-1. Gynecol Oncol. 1980. PMID: 6986327 Review. No abstract available.
IgG4-related Disease with a Cardiac Mass.
Matsumura I, Mitsui T, Tahara K, Shimizu H, Yanagisawa K, Ishizaki T, Koiso H, Takizawa M, Yokohama A, Saitoh T, Hirato J, Murakami H, Handa H, Tsukamoto N. Matsumura I, et al. Among authors: tsukamoto n. Intern Med. 2020 May 1;59(9):1203-1209. doi: 10.2169/internalmedicine.4054-19. Epub 2020 Jan 17. Intern Med. 2020. PMID: 31956206 Free PMC article.
The mechanisms of cancer immunoescape and development of overcoming strategies.
Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y. Yaguchi T, et al. Among authors: tsukamoto n. Int J Hematol. 2011 Mar;93(3):294-300. doi: 10.1007/s12185-011-0799-6. Epub 2011 Mar 5. Int J Hematol. 2011. PMID: 21374075 Review.
Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Eriguchi T, Tsukamoto N, Kuroiwa N, Nemoto T, Ogata T, Okubo Y, Nakano S, Sugawara A. Eriguchi T, et al. Among authors: tsukamoto n. Pract Radiat Oncol. 2021 Jan-Feb;11(1):44-52. doi: 10.1016/j.prro.2020.08.002. Epub 2020 Aug 10. Pract Radiat Oncol. 2021. PMID: 32791232
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).
Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H. Maruyama D, et al. Among authors: tsukamoto n. Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31. Cancer Sci. 2022. PMID: 35909244 Free PMC article. No abstract available.
492 results